[Alloy Therapeutics in Business Wire] Alloy Therapeutics raises $42 million Series D financing to accelerate discovery technology development across biologic modalities

BOSTON–(BUSINESS WIRE)–Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership models designed to fuel innovation.

Read more  here.